132 related articles for article (PubMed ID: 37981082)
21. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
22. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; Jӓnne PA; Gusev A; Kwiatkowski DJ
Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
[TBL] [Abstract][Full Text] [Related]
23. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
[TBL] [Abstract][Full Text] [Related]
25. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
26. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
27. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
28. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
29. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Lam VK; Tran HT; Banks KC; Lanman RB; Rinsurongkawong W; Peled N; Lewis J; Lee JJ; Roth J; Roarty EB; Swisher S; Talasaz A; Futreal PA; Papadimitrakopoulou V; Heymach JV; Zhang J
Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
[TBL] [Abstract][Full Text] [Related]
30. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
31. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
32. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
[TBL] [Abstract][Full Text] [Related]
33. Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
Zito Marino F; Alì G; Facchinetti F; Righi L; Fontanini G; Rossi G; Franco R
Expert Rev Anticancer Ther; 2021 Aug; 21(8):887-900. PubMed ID: 33715580
[No Abstract] [Full Text] [Related]
34. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
35. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
[TBL] [Abstract][Full Text] [Related]
37. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
38. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
[TBL] [Abstract][Full Text] [Related]
39. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
40. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]